Binding Molecules For Bcma And Cd3
Patent No. EP3611193 (titled "Binding Molecules For Bcma And Cd3") was filed by Amgen on Nov 15, 2012. The application was issued on Aug 26, 2026.
Patent Summary
The invention provides an at least bispecific binding molecule for treating or ameliorating multiple myeloma. The molecule comprises two antibody binding domains: a first domain specifically binding to BCMA epitope cluster 3 (amino acid residues 24–41 of SEQ ID NO: 1002; sequence CQLRCSSNTPPLTCQRYC) and a second domain specifically binding to the CD3$\epsilon$ chain of the T cell CD3 receptor complex. This receptor complex, consisting of CD3$\gamma$, CD3$\delta$, and two CD3$\epsilon$ chains, associates with the T cell receptor (TCR) and $\zeta$ chain to generate activation signals in cytotoxic T lymphocytes. The molecule may further include additional functions, such as an Fc constant domain for mediating antibody-dependent cellular cytotoxicity, labels, or therapeutic agents, potentially forming a tri- or multifunctional binding molecule.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3611193
- Application Number
- EP19196304A
- Filing Date
- Nov 15, 2012
- Status
- Granted And Under Opposition
- Jul 24, 2026
- Publication Date
- Aug 26, 2026
- External Links
- Slate, Register , Google Patents